Kornimate/medical-research-clean huggingface dataset:
differential clinical and serologic response in psoriasis and psoriatic arthritis to drug treatment

Conditions: Psoriatic Arthritis

Summary: psoriasis is a multifactorial cutaneous disorders which affects about 100000 patients in taiwan. psoriatic arthritis is also present in about 20\~30 percents. many drugs have been shown to aggravate psoriasis including drugs used in the treatment of psoriatic arthritis. on the contrary, anti-psoriatic drugs are also known to aggravate or induce psoriatic arthritis. psoriasis and psoriatic arthritis are believed to share the same pathogenic lymphocytes, but the differential responses to drugs are intriguing. this also causes problems in the treatment of psoriasis and psoriatic arthritis. recently different serologic markers have been found for the assessment of psoriasis and psoriatic arthritis. recent genetic study showed a different genetic susceptibility genes. we tested the serologic responses of three new biologic drugs used in the treatment of psoriasis and psoriatic arthritis. paired blood samples of the same patients before and after 12 weeks of treatment were used. il6 decreased after alefacept and etanercept but was increased after efalizumab treatment without statistical significance (paired t test: 0.3336、0.2773、0.5904)。il-8 decreased after etanercept but increased after efalizumab and alefacept without statistical significance (paired t test: 0.4031、0.6749、0.2998)。il10 decreased after efalizumab and etanercept, but increased significantly after alefacept treatment (paired t test: 0.7254、0.5123、0.0350)。none of the treatment has a significant effect on tnf-alpha. hc10 decreased after alefacept and efalizumab,but increased after etanercept treatmentwithout statistical significance (paired t test: 0.6589、0.1576、0.1988).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of psoriasis

Keywords: psoriatic arthritis
surge: supporting underrepresented minorities in genomics-based cancer trial enrollment (intervention)

Conditions: Gastrointestinal Cancer; Hematologic Cancer; Thoracic Cancer

Summary: surge aims to increase equity in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. the study is an interventional pilot meant primarily to assess the feasibility of the intervention. the intervention is comprised of a patient navigator, text message questionnaire, and informational video.

supporting underrepresented populations in genomics-based cancer trial enrollment (surge) is a multimodal intervention to address medical literacy and unmet social determinants of health (sdoh) needs as barriers to tumor somatic genomic testing consent among historically underrepresented patients (hup) diagnosed with advanced solid or hematologic malignancies as a prerequisite to precision therapies and/or clinical trial eligibility. our key hypothesis is that video-based education with or without 1:1 patient navigation will address medical literacy and unmet sdoh barriers, supporting hup decision-making about genomic tumor consent. we will conduct a type 1 hybrid implementation effectiveness study among a cohort of hup seeking medical oncology care at two academic and two community practice sites.

Eligibility criteria:
inclusion criteria: * adult (age 18 years or older) * black, latinx, or older adult (age 70 years or older) * scheduled for a new patient consultation * suspected or confirmed advanced malignancy (requiring active treatment) * gastrointestinal, hematologic, or thoracic cancer * dfci patient at longwood/chestnut hill, dfci satellite at st. elizabeth's medical center, or dfci satellite at merrimack valley exclusion criteria: * malignancy or former malignancy that requires only surveillance * not continuing care at a participating dfci site * speaks a language other than english or spanish * unable to provide consent

Keywords: gastrointestinal cancer hematologic cancer thoracic cancer
a study comparing clindamycin and benzoyl peroxide gel 1.2%/3.75% to onexton™ gel in the treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: the objectives of this study are to evaluate the therapeutic equivalence and safety.

the objectives of this study are to evaluate the therapeutic equivalence and safety of the test product clindamycin and benzoyl peroxide gel 1.2%/3.75% to the reference product onexton™ gel (clindamycin and benzoyl peroxide gel 1.2%/3.75%) in the treatment of acne vulgaris and to demonstrate the superiority of the efficacy of these test and reference products over the placebo control.

Eligibility criteria:
inclusion criteria: * healthy male or non pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of acne vulgaris. * must have a minimum ≥ 25 non-inflammatory lesions and ≥ 20 inflammatory lesions and ≤ 2 nodulocystic lesions at baseline on the face. * must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as per the investigator's global assessment. exclusion criteria: * female subjects who are pregnant, nursing or planning to become pregnant during study participation. * a history or presence of crohn's disease, ulcerative colitis, regional enteritis, or antibiotic-associated colitis. * a history of hypersensitivity or allergy to clindamycin, benzoyl peroxide and/or any of the study medication ingredients and its excipients.
a retrospective, observational, multicentre, study to evaluate the safety and performance of polypatch ® vascular patch

Conditions: Artery Stenosis, Carotid; Artery Stenosis; Occlusion of Artery; Stroke

Summary: polypatch® study is rwe multicentre study which examine short and long-term outcomes of using polypatch® when exposed to a larger and more varied population. all data will be retrieved from medical charts for each patient from time of surgery (considered as baseline of study) until a maximum of 3 years after surgery. a minimum of 250 up to a maximum of 300 subjects will be evaluated from 3 to 8 different sites. at least 100 subjects will be evaluated in carotid location and at least 100 in femoral location.


Eligibility criteria:
inclusion criteria: * subjects who did receive polypatch® at least one year ago for vascular angioplasty * subjects ≥ 18 years old exclusion criteria: * none

Keywords: vascular patch polypatch femoral endarterectomy carotid endarterectomy thrombosis
serum presepsin as early predictor for neonatal early-onset sepsis

Conditions: Neonatal Sepsis

Summary: 124 neonates aged ≤7 days with suspected eos were clinically evaluated using snap-ii and gave blood samples for bc, total leucocytic count (tlc), lymphocytic and neutrophil count, and elisa estimation of serum levels of psp, procalcitonin (pct), and tumor necrosis factor-α (tnf-α). enrolled neonates were categorized as confirmed eos: neonates with evident clinical sepsis manifestations and positive bc, suspected eos: neonates with evident clinical sepsis manifestations but had negative bc and no eos included neonates free of evident clinical sepsis manifestations, had negative bc and showed no deterioration till 72-hr after admission.


Eligibility criteria:
inclusion criteria: * included gestational age (ga) of 28-41 weeks and 5-min apgar score of ≥7, and neonatal age of \<7 days exclusion criteria: * including small for gestational age, presence of a chromosomal abnormality, multiple congenital anomalies, genetic syndromes, history of premature rupture of membranes, chorioamnionitis, neonatal asphyxia, and missed inclusion criterion.

Keywords: early-onset neonatal sepsis presepsin clinical scoring early predictors blood culture
osteosarcoma with resectable pulmonary metastasis: a retrospective study

Conditions: Osteosarcoma Metastatic; Pulmonary Disease; Resectable Sarcoma; Survival

Summary: according to euramos-1, 17% of osteosarcoma patients were considered to have metastases at diagnosis. in this selected cohort, the reported 5-year efs from diagnosis of 28% compares well to previous results reported from unselected cohorts of patients with only lung metastases. resection of pulmonary metastases from osteosarcoma is a treatment option which has been shown to correlate with survival benefit and cure in select individuals. these patients are best addressed in a multidisciplinary fashion, with the involvement of a thoracic surgeon with experience in pulmonary metastasectomy. at the same time, the goal of surgical resection of pulmonary metastases from osteosarcoma is to render the patient completely disease free. "tumor debulking" or "cytoreductive surgery" with incomplete resection has not demonstrated any survival benefit for patients with pulmonary metastases. thus open thoracotomy is more preferred than vats. however over the last decade in china, thoracotomy has not been adopted generally. more patients had chosen vats or even hypo-fractionation radiotherapy, such as gamma knife, cyber knife and so on as a local treatment method. this study aims to investigate the survival of consecutive patients who had achieved a first complete surgical remission (cr) during combined-modality therapy on neoadjuvant or adjuvant pkuph-os protocol so as to discuss reasonable local therapy for resectable pulmonary osteosarcoma metastatic lesions.


Eligibility criteria:
inclusion criteria: * histologically confirmed high-grade osteosarcoma reviewed by the pathology committee of peking university people's hospital * pulmonary nodules by chest ct confirmed by later scan as pulmonary metastasis * a first complete remission (cr) had been achieved * intended first-line treatment included pre- and postoperative chemotherapy according to the pkuph-os protocol as well as local therapy of all operable lesions exclusion criteria: * lost to follow up * patients with severe or uncontrolled medical disorders that could jeopardize the outcomes of the study. these confounding conditions included, cardiac clinical symptoms or disease with left ventricular ejection fraction\<50%, and hypertension that could not be well controlled with antihypertensive drugs.

Keywords: osteosarcoma pulmonary metastasis resectable event-free survival
effects of fluid infusion on postoperative vomiting in pediatric patients undergoing otorhinolaryngological surgery

Conditions: Postoperative Nausea and Vomiting

Summary: otorhinolaryngological surgery is one of the commonly applied procedures surgical treatments of children in the world. postoperative vomiting (pov) is an important part of the management of pediatric anesthesia in this surgery that is also related with these surgical procedures. postoperative vomiting is one of the most common complication of this surgery and may cause patients to receiving anesthesia again and stay longer in the hospital.the use of effective fluid therapy might be a safe way to reduce pov. there are many studies of fluid therapy adult patients on the other hands the number of children studies are limited. the aim of this study was to evaluate the pov effect of intraoperative hydration with 0.9 nacl solution in children undergoing otorhinolaryngological surgery.

after institutional ethics committee approval and written informed parental consent, asa physical status i or ii, aged 2-14 year, who were undergoing elective day case otorhinolaryngological surgery under general anaesthesia, were screened for eligibility for enrollment in this prospective, randomized, double blind, placebo controlled study. in the operating room, after routine monitoring, general anaesthesia was induced with %8 sevoflurane in 100% oxygen by a face mask with spontaneous ventilation. patients were randomly assigned to one of the two groups. randomization was carried out using a computer-generated random numbers. the control group (group i) received ≤10 ml kg-1 h-1 and the high volüme group ( group ii) received \>30 ml kg-1h-1 of intravenous %0.9 nacl solution.before tracheal intubation, all subjects received propofol 2:5mg kg-1, fentanyl 1µg kg-1 and rocuronium 0.6 mg kg-1. after tracheal intubation, anaesthesia was maintained with 40% mixture of oxygen/nitrous oxide and 2% sevoflurane. the solution appears to be covered via an infusion pump was used. during anaesthesia, all patients received intravenous paracetamol 10 mg kg-1 for postoperative pain . following extubation, until the transfer of the patient from the time of the pacu nausea, vomiting or both were recorded.. retching efforts in the pacu were recorded as nausea evaluated. both nausea and vomiting were assessed on a four point scale: 0=no nausea/vomit, 1=mild nausea/vomit, patient not requesting metoclopramide, 2=nausea/vomit, patient requesting metoclopramide and 3=nausea/vomit resistant to treatment at the first episode of severely nause and vomiting, or both, a rescue antiemetic consisting of intravenous ondansetron was administered. intensity of pain was evaluated using children's hospital east ontario pain scale (cheops). knowledge collection for posoperative pain to pacu arrival and departure was performed by a postanesthesia care unit (pacu) nurses who blinded to the procedure the amount of fluid therapy.

Eligibility criteria:
inclusion criteria: * 2-14 years * asa i-ii exclusion criteria: * gastroesafageal reflu * premedication antiemetic

Keywords: fluid infusion vomiting otorhinolaringology
initiation of cpap for newly diagnosed osa in hospitalized heart failure patients

Conditions: Sleep Apnea, Obstructive; Heart Failure

Summary: the study aimed to examine the effect of continuous positive airway pressure (cpap) initiation for newly diagnosed obstructive sleep apnea (osa) in hospitalized heart failure patients on reducing 30-day hospital readmission rate through a clinical trial.

following consent adult patients hospitalized with a medical history of heart failure and meeting study eligibility criteria will be screened for obstructive sleep apnea using the ohio sleep medicine institute preoperative questionnaire. if the probability of sleep apnea is high (sleep apnea clinical score \>15) then participants will complete the epworth daytime sleepiness scale and the minnesota living with heartfailure questionnaire. the patient will then be evaluated by the sleep medicine team with a portable polysomnography monitor which has been shown to be equivalent to standard in-laboratory polysomnography. all participants with apnea-hypopnea index (ahi) ≥ 5events/h in whom sleep disordered breathing is confirmed by sleep medicine physician will be eligible for randomization. participants will be randomized into an auto-adjusting continuous positive airway pressure (cpap) group or standard of care (control) group. cpap arm (intervention): cpap education and discharge with auto-adjusting continuous positive airway pressure (cpap) in addition to usual standards of clinical care for heart failure. the auto-cpap group will be scheduled for follow-up with a phone call at 2 - 3 weeks post discharge, then in sleep medicine clinic at 1 month (+2 weeks) and 6 months (+2 weeks) to assess their progress on cpap. standard of care arm (comparator): cpap initiation per standard of care based on approval by insurance company and dme company with management as per usual standards of clinical care for heart failure. this group will be scheduled for follow-up with a phone call at 2- 3 weeks post discharge and then in sleep medicine clinic at 1 month (+2 weeks) and 6 months (+2 weeks) to assess their progress.

Eligibility criteria:
inclusion criteria: * hospitalized having a documented history of heart failure * anticipated hospitalization of more than 24 hours * subject has obtained a score of \> 15 on the ohio sleep medicine institute preoperative questionnaire. * subject has an apnea-hypopneas index (ahi) of \> 5/h as confirmed by sleep medicine physician exclusion criteria: * the presence of any conditions that the investigator feels will interfere with the use of cpap
effects of modified t'ai chi on symptoms in older adults with osteoarthritis

Conditions: Osteoarthritis

Summary: the purpose of this study was to evaluate the effects of tc for arthritis on physical function, pain, and stiffness in older adults with knee/hip oa. two hypotheses were tested: 1. individuals in the tc group will demonstrate greater improvements in physical function compared to control group participants. 2. individuals in the tc group will demonstrate greater decreases in pain and stiffness compared to control group participants.

exercise is considered a vital component of osteoarthritis (oa) treatment. t'ai chi (tc) is a unique exercise intervention with low-velocity movements. few studies have addressed the effects of tc on arthritis symptoms and function. tc for arthritis was modified specifically for people with oa and consists of a standardized set of forms. the purpose of this study was to evaluate the effectiveness of a low-dose tc for arthritis on physical function, pain, and stiffness in individuals with oa. twenty-seven older adults with oa (mean age-81.3 years) completed an 8 week non-randomized controlled pre-post test quasi-experimental design study of tc for arthritis. physical function, pain, and stiffness were measured at baseline and 8 weeks for the tc and control groups using the womac™ 3.1 index. qualitative data from interviews and participant observations were analyzed in order to understand the participants' expectations and experiences with tc.

Eligibility criteria:
inclusion criteria: * ability to walk independently, * speak and understand english, * understand the consent process; and * give informed consent. exclusion criteria: * participation in rehabilitation or another tc class, * at the time of recruitment; and * inability to confirm medical stability for safe participation with healthcare provider.

Keywords: t'ai chi osteoarthritis exercise older adults
little lungs study

Conditions: Invasive Mechanical Ventilation; Severe Respiratory Distress Syndrome

Summary: this clinical trial is being done to evaluate the clinical response and safety of late surfactant treatment with budesonide in extremely preterm infants requiring mechanical ventilation at 7-14 days of age. the main questions it aims to answer are: * do the combined drugs improve the respiratory severity score (rss) * is the combination safe participants will receive three doses of the study drug.


Eligibility criteria:
neonate inclusion criteria: * gestational age 22 0/7 to 28 6/7 weeks at birth * age 7-14 days * need invasive mechanical ventilatory support * have at least one parent/guardian who is able to provide parental permission in english or spanish birthing parent inclusion criteria: * have a baby who meets neonate eligibility criteria and enrolls in the study. * is able to provide consent in english or spanish neonate exclusion criteria: * major congenital anomalies * history of pulmonary hemorrhage * antibiotic use within 48 hours * prior treatment with corticosteroids for prevention of lung disease * indomethacin or ibuprofen use within 72 hours * have a birth parent aged less than 18 years * respiratory severity score less than 2.4 * not expected to survive for greater than 7 days at enrollment birthing parent exclusion criteria: * is aged less than 18 years

Keywords: premature birth
parents as the agent of change for childhood obesity

Conditions: Obesity

Summary: the overall intent of this study is to explore a promising mode for delivering treatment for childhood obesity via parent education only, and to evaluate the cost effectiveness compared to the current gold standard treatment of parent-and-child dual education.

this study is a randomized clinical trial in which 150 overweight 8-12 year old children and their parent will be randomly assigned by the gender of the child to one of two conditions; a parent-only intervention or a parent + child intervention. both treatment arms will provide behavioral treatment for childhood obesity for 5 months, and participants will be followed for 18-months post-treatment. assessments will occur at baseline, immediately post-treatment, 6-12- and 18-months post-treatment. the overall intent of this study is to explore a promising mode for delivering treatment for childhood obesity (parent-only), and to evaluate the cost effectiveness compared to the current gold standard treatment of parent + child. results of these studies will be utilized as evidence to recommend changes in the standard treatment for childhood obesity. this program of research is critical for exploring and developing interventions that mobilize parents to intervene with their overweight and obese children. the timing of this research is optimal given the increase in childhood obesity in the united states, and the need for disseminative intervention and prevention programs.

Eligibility criteria:
inclusion criteria: * overweight child 8-12 years of age and above the 95th% for age and gender * an overweight (bmi \> 25) parent willing to participate and attend all treatment meetings * eligible parent who can read at a minimum of an 8th grade level * family willing to commit to 5 months of treatment attendance, and follow-up for 18 months post-treatment. exclusion criteria: * major child psychiatric disorder diagnoses * child diagnoses of a serious current physical disease (such as diabetes) for which physician supervision of diet and exercise prescription are needed (self-report) * family with restrictions on types of food, such as food allergies, religious, or ethnic practices that limit the foods available in the home * child with physical difficulties that limit the ability to exercise * child with an active eating disorder (based on ede interview) * families where children or parents are involved in swimming or weight training more than 5 hours per week * major parent psychiatric disorder

Keywords: obesity overweight overweight children overweight parents families with overweight child body mass index bmi weight childhood obesity diet treatment parent modeling traffic light diet stop light diet
study of anlotinib in patients with soft tissue sarcoma（sts）(alter0203)

Conditions: Soft Tissue Sarcoma

Summary: compare the effects and safety of anlotinib with placebo in patients with soft tissue sarcoma.


Eligibility criteria:
inclusion criteria: * signed and dated informed consent * histological documentation of soft tissue sarcoma,including synovial sarcoma、leiomyosarcoma、alveolar soft part sarcoma、undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma、adipocytic tumors、fibrosarcoma、clear cell sarcoma、epithelioid sarcoma，with measurable disease. * within the past 6 months, using at least one failure of chemotherapy regimens (including anthracycline-based) in treating patients(except alveolar soft part sarcoma) * 18-70years,ecog ps:0-1,life expectancy of more than 3 months * main organs function is normal * the woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 6 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; the man patients who must agree to take contraceptive methods during the research and within another 6 months after it exclusion criteria: * prior treatment with anlotinib * with pleural effusion or ascites, cause respiratory syndrome * accepted the vascular endothelial growth inhibitor class targeted drug treatment of patients * plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the medicine-taking period of this research, including cytotoxic therapy, signal transduction inhibitor, and immunotherapy (or who use mitomycin c within 6 weeks before taking the treatment with experimental drug); the patients who have already taken extended field radiotherapy (ef-rt) within 4 weeks before grouping or limited field radiotherapy with proposed assessment of nidus within 2 weeks before grouping * symptoms of brain metastases cannot be controlled and treated within less than 2 months * with severe and failed to controlled diseases * occurred venous thromboembolic events within 6 months